«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 15

Page:

2829-2833

Research Field:

Publishing date:

Info

Title:

Association between the expression of p16 protein and the status of CDKN2A gene deletion in low-grade astrocytomas with IDH mutant

Author(s):

WANG Chun; LI Ang; ZHENG Aiping; CHEN Jiakang; HUANG Chuqiang; YIN Weihua; LI Jian

Department of Pathology,Peking University Shenzhen Hospital,Guangdong Shenzhen 518036,China.

Keywords:

astrocytoma; IDH mutation; p16 protein; CDKN2A gene

PACS:

R739.4

DOI:

10.3969/j.issn.1672-4992.2023.15.012

Abstract:

Objective:To investigate the feasibility of using p16 protein immunostaining as an alternative to replace the homozygous deletion test of cyclin dependent kinase inhibitor 2A (CDKN2A) gene in IDH mutant astrocytomas.Methods:Forty-two cases of glioma with a histological diagnosis of low-grade astrocytoma (WHO grade 2) and concurrently carrying with IDH mutation were retrieved from our hospital.The expression of p16 protein was detected by immunohistochemistry.Based on the expression rate of p16 protein in the nucleus or cytoplasm respectively,the tumors were classified into five groups:Negative (0% positive rate),low expression (0%£¼positive rate¡Ü10%),moderate expression (10%£¼positive rate¡Ü25%),high expression (25%£¼positive rate¡Ü50%),and overexpression (positive rate£¾50%).Fluorescence in situ hybridization (FISH) was performed to evaluate the homozygous deletion (HmD) and heterozygous deletion (HtD) of CDKN2A gene.Fisher's exact test was employed to evaluate the correlation between p16 protein expression and the deletion status of CDKN2A gene.Results:The expression level of p16 protein in the nucleus was significantly correlated with CDKN2A HmD (P£¼0.001).The cases in the negative expression group (4/4,100%) consistently showed CDKN2A HmD,while no cases in the moderate,high,and overexpression groups (22/22,100%) demonstrated HmD.However,no constant relationship was observed in p16 low expression group,as 3 cases (3/16,18.75%) detected HmD while 13 cases (13/16,81.25%) did not.On the other hand,p16 protein expression in the nucleus did not correlate with CDKN2A HtD (P=0.228).In addition,p16 protein expression in the cytoplasm did not correlate with either CDKN2A HmD (P=0.086) or HtD (P=0.884).Conclusion:As far as the histologically low-grade astrocytoma with IDH mutant was concerned,the negative expression (0% positive rate) or moderate and above expression (positive rate£¾10%) of p16 protein in the nucleus suggested the presence or absence of CDKN2A HmD,respectively.In the above expression range,p16 protein exhibited well-matched relationships with the status of CDKN2A HmD,and could be utilized to assist the pathological diagnosis and grading in astrocytoma.In contrast,low expression of nucleus p16 protein (0%£¼positive rate¡Ü10%) could not predict the HmD status of CDKN2A,and genetic analysis on CDKN2A is still needed under such condition.

References:

£Û1£ÝRENI M,MAZZA E,ZANON S,et al.Central nervous system gliomas£ÛJ£Ý.Crit Rev Oncol Hematol,2017,113:213-234.
£Û2£ÝHAN S,LIU Y,CAI SJ,et al.IDH mutation in glioma:molecular mechanisms and potential therapeutic targets£ÛJ£Ý.Br J Cancer,2020,122(11):1580-1589.
£Û3£ÝMURUGAN AK,ALZAHRANI AS.Isocitrate dehydrogenase IDH1 and IDH2 mutations in human cancer:Prognostic implications for gliomas£ÛJ£Ý.Br J Biomed Sci,2022,79:10208.
£Û4£ÝBRAT DJ,ALDAPE K,COLMAN H,et al.cIMPACT-NOW update 5:recommended grading criteria and terminologies for IDH-mutant astrocytomas£ÛJ£Ý.Acta Neuropathol,2020,139(3):603-608.
£Û5£ÝAPPAY R,DEHAIS C,MAURAGE CA,et al.CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas£ÛJ£Ý.Neuro Oncol,2019,21(12):1519-1528.
£Û6£ÝPURKAIT S,JHA P,SHARMA MC,et al.CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry£ÛJ£Ý.Neuropathology,2013,33(4):405-412.
£Û7£ÝHUANG LE.Impact of CDKN2A/B homozygous deletion on the prognosis and biology of IDH-mutant glioma £ÛJ£Ý.Biomedicines,2022,10(2):246.
£Û8£ÝBALE TA,ROSENBLUM MK.The 2021 WHO classification of tumors of the central nervous system:An update on pediatric low-grade gliomas and glioneuronal tumors £ÛJ£Ý.Brain Pathol,2022,32(4):e13060.
£Û9£ÝFOULKES WD,FLANDERS TY,POLLOCK PM,et al.The CDKN2A (p16) gene and human cancer£ÛJ£Ý.Mol Med,1997,3(1):5-20.
£Û10£ÝNALABOTHULA N,LAKKA SS,DINH DH,et al.Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death£ÛJ£Ý.Int J Oncol,2007,30(3):669-678.
£Û11£ÝPURKAIT S,SHARMA V,JHA P,et al.EZH2 expression in gliomas:Correlation with CDKN2A gene deletion/p16 loss and MIB-1 proliferation index£ÛJ£Ý.Neuropathology,2015,35(5):421-431.
£Û12£ÝPARK JW,KANG J,LIM KY,et al.The prognostic significance of p16 expression pattern in diffuse gliomas£ÛJ£Ý.J Pathol Transl Med,2021,55(2):102-111.
£Û13£ÝYANG RR,SHI ZF,ZHANG ZY,et al.IDH mutant lower grade (WHO grades II/III) astrocytomas can be stratified for risk by CDKN2A,CDK4 and PDGFRA copy number alterations£ÛJ£Ý.Brain Pathol,2020,30(3):541-553.
£Û14£ÝMIETTINEN H,KONONEN J,SALLINEN P,et al.CDKN2/p16 predicts survival in oligodendrogliomas:comparison with astrocytomas£ÛJ£Ý.J Neurooncol,1999,41(3):205-211.
£Û15£ÝBORTOLOTTO S,CHIAD¦X-PIAT L,CAVALLA P,et al.CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas£ÛJ£Ý.Int J Cancer,2000,88(4):554-557.
£Û16£ÝREIS GF,PEKMEZCI M,HANSEN HM,et al.CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas£ÛJ£Ý.J Neuropathol Exp Neurol,2015,74(5):442-452.
£Û17£ÝBURNS KL,UEKI K,JHUNG SL,et al.Molecular genetic correlates of p16,cdk4,and pRb immunohistochemistry in glioblastomas£ÛJ£Ý.J Neuropathol Exp Neurol,1998,57(2):122-130.
£Û18£ÝSHIMA K,NOSHO K,BABA Y,et al.Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers:Cohort study and literature review £ÛJ£Ý.Int J Cancer,2011,128(5):1080-1094.

Memo

Memo:

¹ã¶«Ê¡ÉîÛÚÊпƴ´Î¯×ÔÈ»¿Æѧ»ù½ð×ÊÖú£¨±àºÅ£ºJCYJ20220531094017039£©

Common functions

Last Update: 2023-06-30